Download Supplemental File

SUPPLEMENTAL MATERIAL
SUPPLEMENTARY TABLE 1. Summary of the key clinical outcomes of different radiotracers currently used in the clinical setting or under research for palliative
treatment of bone metastases.1-6
Radiotracer
%bone uptake
Main elimination route
Response to therapy (%)
Duration of therapeutic response (months)
Side effects
85
Urinary
50-87
2-7
Significant
SrCl2
55
Urinary
65-90
3-6
Significant
Y-EDTMP
45-50
Urinary
--
--
--
Sn-DTPA
77
Urinary
60-83
4-5
Mild
153
Sm-EDTMP
65
Urinary
55-83
2-3
Moderate
166
Ho-DOTMP
16-54
Urinary
NE
NE
Moderate
Tm-EDTMP
50-55
Urinary
--
--
--
70
Urinary
NE
NE
Mild
54-80
Urinary
55-80
NE
Mild
32
P-ortofosfato
89
90
117m
170
177
Lu-DOTMP
177
Lu-EDTMP
186
Re-HEDP
55
Urinary
55-85
2-4
Mild
188
Re-HEDP
30
Urinary
64-77
3-6
Mild
223
41
Intestinal
58-75
2-3
Moderate
RaCl2
Legend: NE – not established.
Note: Data for 90Y-EDTMP and 170Tm-EDTMP is preclinical.
1
REFERENCES:
1.
International Atomic Energy Agency, Radiation Biology: A Handbook for Teachers and
Students, Training Course Series 42, Vienna, 2010
2.
Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46 Suppl 1(1):38S47S.
3.
Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin
Nucl Med 2005, 35(2): 152-8.
4.
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study
of radium-223 chloride for the palliation of painful bone metastases in patients with castrationresistant prostate cancer. Eur J Cancer. 2012; 48(5):678-86.
5.
Saeed S, Zaknun J, Jameel G, et al.
177
Lu-EDTMP - A bone pain palliating agent:
Biodistribution and skeletal uptake in osseous metastatic patients. J Nuc Med. 2011:52 (Supp
1):1750
6.
Yuan J, Liu C, Liu X, et al. Efficacy and safety of
177
Lu-EDTMP in bone metastatic pain
palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nuc
Med. 2013: 38(2):88-92
2